erlotinib hydrochloride has been researched along with Hyperglycemia, Postprandial in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chomphoo, S; Khawkhiaw, K; Ruangpratyakul, T; Saengboonmee, C; Seubwai, W; Sorin, S; Thithuan, K; Wongkham, S; Zeng, F; Zhou, Y | 1 |
1 other study(ies) available for erlotinib hydrochloride and Hyperglycemia, Postprandial
| Article | Year |
|---|---|
High glucose enhances the aggressiveness of lung adenocarcinoma via activating epidermal growth factor receptor/signal transducer and activator of transcription 3 pathways.
Topics: Adenocarcinoma of Lung; Animals; Cell Line, Tumor; Cell Movement; Cell Proliferation; ErbB Receptors; Erlotinib Hydrochloride; Glucose; Humans; Hyperglycemia; Lung Neoplasms; Mice; STAT3 Transcription Factor | 2023 |